• Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Life can be better
    We are developing drug products isolated from plant extracts
    with history in traditional medicine.
    Read more
  • Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Improving health
    Improving health and wellbeing of the people
    is our ultimate goal at Mercury Pharmaceuticals.
    Read more
  • Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    Mercury Pharmaceuticals
    ENTREPRENEURIAL MINDSET
    Hands-on approach to manage projects with proactivity and flexibility.
    Read more

Welcome to Mercury Pharmaceuticals

We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.

More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.

Mercury Pharmaceuticals
Technology Assessment
Mercury Pharmaceuticals
Systems Research
Mercury Pharmaceuticals
Innovation Assessment
Mercury Pharmaceuticals
Clinical Trials

OUR Science

The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.

Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.

  • NeuroscienceAmong the global leaders in Neuroscience
  • OncologyTreatments for niche cancers.
  • Research & Development Building a sustainable R&D pipeline.
  • Clinical trialsTesting new treatments and ensure their efficacy and safety by conducting clinical trials.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

15

Sep 2026

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure–free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, Republic of Korea.

READ MORE
A study of more than 21,000 adults found an unusual link between psilocybin and diet

15

Sep 2026

A study of more than 21,000 adults found an unusual link between psilocybin and diet

Using data from more than 21,800 adults in two UK birth cohorts, researchers found that lifetime psilocybin and LSD use was associated with stronger pro-environmental attitudes and a greater likelihood of following a vegetarian diet, with psilocybin showing the clearer dietary pattern. Mediation analyses suggested that environmental attitudes statistically accounted for the psilocybin-vegetarianism association and part of the association with lower red meat consumption, but the observational design cannot establish causation.

READ MORE
T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

15

Sep 2026

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

READ MORE

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.